The original Hollings Cancer Center (HCC) Building, home to outpatient cancer services and research, was completed in 1993. Just over a decade later due to the pressing need to expand the footprint for clinical and research activities, MUSC secured $98M to add a seven-story tower and significantly renovate the original HCC Building. These projects were completed in 2007. During the initial Cancer Center Support Grant (CCSG) project period (2009-present), the HCC leadership has continued to ensure that the available facilities match the HCC's strategic plans to grow its laboratory, clinical, and cancer control-based research programs. The leadership has worked closely with the MUSC administration and architectural and engineering teams to design additional state-of-the-art facilities and space. This has led to the construction of the Drug Discovery Building (DDB) and Bioengineering Building (BEB) in late 2011, a $120M investment. The HCC has assignment of approximately three and a half floors within these two new buildings. As shown in Table 1, the total HCC-controlled space has increased to 270,174 gross ft[2], a 33% increase since the initial CCSG submission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-06
Application #
8695842
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2014-06-20
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$66,507
Indirect Cost
$22,087
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46
Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6
Podbielska, Maria; Szulc, Zdzisław M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039
Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25
Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95
Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30
Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7
Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50
Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203
Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263

Showing the most recent 10 out of 311 publications